According to the report, the size of the Asia Pacific Next-Generation Antibody Therapeutics Market is estimated to grow USD 1.77 billion by 2027 from USD 0.88 billion in 2022, growing at a CAGR of 14.9% between 2022 to 2027. It captures 20% of the global market.
Biotechnology and pharmaceutical companies are clinically developing the next-generation antibody therapies for different disease indications accredited to the rise in market growth. Increasing demand for biologics drugs used for treating patients with chronic disorders is leveraging market growth. Rising census count and economies, particularly in developed countries, are projected to lead the market growth. Escalating government support for research and development activities and growing demand for superior healthcare facilities are surging the market demand. A growing number of cancer cases, as the next generation antibody therapy works as an effective therapy accredited to the market growth. Factors like rising government initiatives for supporting research and development activities and developing healthcare infrastructure are fueling the market. New product launches with regular government approvals are incrementing the next-generation antibody therapeutics market demand.
However, the huge capital required for research and development activities in developing antibody therapies negatively affects market growth. The governments of different nations have imposed strict rules and guidelines regarding the usage of antibodies. This factor is curbing the increase in the market. Time taking procedural approvals and limited FDA approvals for drugs and other products restrict the growth in the market.
This research report on the Asia Pacific Next-Generation Antibody Therapeutics Market has been segmented and sub-segmented into the following categories:
Based on the region, the Asia Pacific is likely to be the fastest-growing market with the highest CAGR in the forecast period. The economic boom in the emerging economies of India and China are the reasons for this.
The Asia-pacific market is accredited due to factors like increasing antibody-drug conjugate usage and rapid growth in biosimilar antibodies and engineered antibodies creating new opportunities for the market demand. Increasing research and development activities united with crucial players to manufacture adequate and enhanced drugs escalates the market demand. China is leading the market with the largest share. The market in China is driven by the government, spending considerable investments in improving healthcare during the COVID-19 pandemic. The escalating number of cost-efficient research services is majorly contributing to the market growth. Japan and China are next to China in leading the next-generation antibody therapeutics market. Rising advancements among the monoclonal antibody technology are likely to foster market growth. A growing number of government initiatives regarding the research and development of drug development and increasing disposable income positively influence the market demand. The rest of APAC is expected to have noticeable growth in the market.
Some of the notable companies dominating the Asia Pacific Next-Generation Antibody Therapeutics Market include Roche, Seattle Genetics, Takeda, Dyax Corp., and Immunogen, Amgen, Inc., Biogen, Kyowa Hakko Kirin Co., Ltd., AstraZeneca, Pfizer, Inc., and Xencor, Inc.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1.2 Antibody-Drug Conjugates (ADCs)
5.1.3 Bispecific Antibodies (BsAbs)
5.1.4 Fc Engineered Antibodies
5.1.5 Antibody Fragments and Antibody-like Proteins
5.1.6 Biosimilar Antibody Products
5.1.7 Y-o-Y Growth Analysis, By Technology
5.1.8 Market Attractiveness Analysis, By Technology
5.1.9 Market Share Analysis, By Technology
5.2 Therapeutic Application
5.2.3 Autoimmune/Inflammatory Diseases
5.2.4 Y-o-Y Growth Analysis, By Therapeutic Application
5.2.5 Market Attractiveness Analysis, By Therapeutic Application
5.2.6 Market Share Analysis, By Therapeutic Application
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
22.214.171.124 By Geographical Area
126.96.36.199 By Technology
188.8.131.52 By Therapeutic Application
6.1.4 Market Attractiveness Analysis
184.108.40.206 By Geographical Area
220.127.116.11 By Technology
18.104.22.168 By Therapeutic Application
6.1.5 Market Share Analysis
22.214.171.124 By Geographical Area
126.96.36.199 By Technology
188.8.131.52 By Therapeutic Application
6.5 South Korea
6.7 Rest of APAC
7. Strategic Analysis
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Seattle Genetics
8.4 Dyax Corp.
8.6 Amgen, Inc.
8.8 Kyowa Hakko Kirin Co., Ltd.
8.10 Pfizer, Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, Collaborations, and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.